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Abstract
Prostaglandin E2 (PGE2), a pleiotropic immunomodulatory molecule, and its free radical catalyzed isoform, iso-PGE2, are
frequently elevated in the context of cancer and chronic infection. Previous studies have documented the effects of PGE2 on
the various CD4+ T cell functions, but little is known about its impact on cytotoxic CD8+ T lymphocytes, the immune cells
responsible for eliminating virally infected and tumor cells. Here we provide the first demonstration of the dramatic effects
of PGE2 on the progression of human CD8+ T cells toward replicative senescence, a terminal dysfunctional state associated
multiple pathologies during aging and chronic HIV-1 infection. Our data show that exposure of chronically activated CD8+ T
cells to physiological levels of PGE2 and iso-PGE2 promotes accelerated acquisition of markers of senescence, including loss
of CD28 expression, increased expression of p16 cell cycle inhibitor, reduced telomerase activity, telomere shortening and
diminished production of key cytotoxic and survival cytokines. Moreover, the CD8+ T cells also produced higher levels of
reactive oxygen species, suggesting that the resultant oxidative stress may have further enhanced telomere loss.
Interestingly, we observed that even chronic activation per se resulted in increased CD8+ T cell production of PGE2,
mediated by higher COX-2 activity, thus inducing a negative feedback loop that further inhibits effector function.
Collectively, our data suggest that the elevated levels of PGE2 and iso-PGE2, seen in various cancers and HIV-1 infection, may
accelerate progression of CD8+ T cells towards replicative senescence in vivo. Inhibition of COX-2 activity may, therefore,
provide a strategy to counteract this effect.
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Introduction
Lipid mediators have long been recognized as key regulators of
inflammation and homeostasis. Prostaglandins constitute one of
the most important families of these mediators. In particular,
prostaglandin E2 (PGE2), a common arachidonic acid-derived
eicosanoid produced by cyclooxygenases (COX1 and COX2), is
involved in a wide variety of physiological events. It is markedly
increased during inflammatory processes, and it helps promote
vasodilation; moreover, its chronic biological effects have been
linked to the pathogenesis of certain malignancies and HIV
disease. Within the immune system, PGE2 modulates such critical
processes as cytokine production, differentiation, proliferation,
migration and antigen presentation [1,2].
Several pathologies suggest a role for PGE2 in specifically
modulating the function of T cells. For example, CD8+ T cells
from HIV-infected persons have increased intracellular cyclic
AMP (cAMP), a downstream target of the PGE2 signaling cascade.
Furthermore, elevated serum levels of prostaglandins correlate
with worse clinical prognoses in HIV/AIDS [3,4]. In addition, T
cells from patients with PGE2-secreting cancers show decreased
proliferation in response to anti-CD3 antibody stimulation [5].
Interestingly, aging in both mice and humans is associated with
increased PGE2 secretion by activated macrophages, which could
potentially impact responses of T cells in their proximity [6]. A
great deal of the PGE2/immunology research has been focused on
the development and differentiation of the CD4+ T cell subset,
particularly in regard to its role in facilitating expansion of Th1
and Th17 cells [7,8]. However, little is known about the effect of
PGE2 on CD8+ T cells, for example, with respect to their
progression towards replicative (cellular) senescence, a state of
functional dysregulation and irreversible cell cycle arrest consid-
ered to be a contributor to failed immune responses during
chronic infection and aging.
Oxidative stress, previously documented to increase the levels of
PGE2 and its free-catalyzed isoform, iso-PGE2 [9], is also known
to accelerate the process of replicative senescence. In this study, we
addressed the question of whether PGE2 and iso-PGE2 themselves
might have effects on replicative senescence that are distinct from
those caused by oxidative stress. To address this question, we used
a well-established in vitro model of T cell replicative senescence to
measure changes in CD8+ T cell proliferation, telomerase activity,
production of key cytokines, and expression of costimulatory
molecules during chronic activation in the presence of these
immunomodulators. Our data show that exposure to exogenous
PGE2 and iso-PGE2 accelerates the senescence trajectory and
associated effector functions of CD8+ T cells. Importantly,
persistent, chronic stimulation of T cells per se increases COX-2
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activity in CD8+ T cells, leading to endogenous production of
PGE2. Our data suggest a mechanism by which cancer cells, aging
and chronic infections may each contribute to T cell dysfunction
and senescence.
Materials and Methods
Ethics Statement
All study participants for this study were recruited from the Los
Angeles metropolitan area. This study was approved by the
University of California, Los Angeles Medical Institutional Review
Board and each participant provided written, informed consent
per the approved protocol.
Cell Cultures
Human peripheral blood samples from self-reported healthy
donors were acquired by venipuncture after informed consent, and
in accordance with the UCLA IRB. After centrifugation, the layer
of peripheral blood mononuclear cells (PBMC) was carefully
removed and washed twice in complete RPMI (5% fetal bovine
serum, 10 mM Hepes, 2 mM glutamine, 50 IU/mL penicillin/
streptomycin). The EasySep CD8+ enrichment kit (Miltenyi
Biotec) was used to isolate CD8+ T cells by negative selection,
and purity of the cells was verified by flow cytometry (routinely .
90% CD8+). Cultures of purified T cell were established as
described previously [10]. Briefly, CD8+ T cells were exposed to
diluent (DMSO) or to 100 nM–1 mM PGE2, iso-PGE2, the EP2
antagonist AH6809, EP4 antagonist CAY10598, or a COX-2
inhibitor CAY10404 (all from Cayman Chemical) for 30 minutes
and then activated with anti-CD2/CD3/CD28 microbeads, used
as surrogate antigen (Miltenyi Biotec) with 10 ml microbead
cocktail added for every 16106 cells. Stimulation and the
modulator pre-treatment were repeated every 14–17 days. In
some experiments, 500 nM butaprost (EP2 agonist), 500 nM
misoprostol (EP4, EP3. EP1. EP2 agonist; each from Cayman
Chemical), 1 mM Forskolin or H89 dihydrochloride (both Tocris
Bioscience) were added. Cultures were supplemented with
recombinant IL-2 (20 U/mL). Every 3–4 days, viable cell
concentration was determined by trypan blue exclusion, and
when the concentration reached $86105/ml, cells were sub-
cultivated to a density of 56105 cells/ml. Population doublings
(PD) were determined according to the formula: PD= log2 (final
cell concentration/initial cell concentration).
Quantitative PCR
Gene expression was evaluated by quantitative polymerase
chain reaction (qPCR) analysis. In brief, after extraction by
RNeasy Mini kit (Qiagen), 500 ng of RNA from T cells was
reverse-transcribed with the iScript cDNA synthesis kit (Bio-Rad).
The qPCR assays were performed using the Bioline SensiFAST
SYBR Kit and CFX 96 (Bio-Rad). The housekeeping gene, 36B4,
was used as an internal control. The sequences of the primers were
designed using Primer 3 software, listed below. Samples were run
in triplicate in a 96-well plate using the settings of 95uC for 2
minutes, 95uC for 5 s and 60uC for 15 min (single fluorescence
measurement) with the 2nd and 3rd step repeated for 39 cycles.
Primer sequences are listed on Table 1.
Flow Cytometry
Surface expression of CD28, CD8, and CD3 was examined by
immunostaining and flow cytometry. Cells were incubated with
fluorescently labeled anti-CD3, -CD8, -CD28, -CD25, fluoro-
phore conjugated antibodies (BD Biosciences) at 4uC for 20 min,
washed, and fixed in PBS containing 1% paraformaldehyde.
Parallel samples were incubated with Ig isotype control antibody
or secondary Abs (BD Biosciences). For intracellular staining, cells
were stimulated for 5 hr with anti-CD2/CD3/CD28 microbeads
with or without the immunomodulators, treated with Golgistop for
6 hours, permeabilized and stained with PE-anti-IFN-c and FITC-
anti-TNF-a antibodies using the Cytofix/Cytoperm Plus kit (BD
Biosciences). All samples were analyzed on a FACSCalibur flow
cytometer (Beckton Dickson). Fluorescence data from at least
25,000 cells were acquired. Analysis of data was performed using
Cell Quest Pro (BD Biosciences).
Telomerase Activity Measurements
Telomerase activity was determined using a modified version of
the Telomerase Repeat Amplification Protocol (TRAP) as
previously described [11]. Briefly, for each sample 16106 CD8+
cells were pelleted and washed twice with PBS. Cell pellets were
lysed in 100 mL of M-PER Mammalian Protein Extraction
Reagent (Pierce Biotechnology) and allowed to incubate on ice
for 1 hour. To control for inter-sample cell number variance,
samples were normalized according to nucleic acid concentration,
which was determined using spectrophometric readings for
dsDNA. The endogenous telomerase present in the cell extract
adds telomeric repeats to the telomerase substrate (TS), a
nontelomeric oligonucleotide. The extension products are then
amplified several-fold by PCR carried out by Taq polymerase
using a Cy-5-labeled forward primer (TS: 592/5Cy5/
AATCCGTCGACGCAGAGTT) as a substrate for telomerase-
mediated addition of TTAGGG repeats, and an anchored reverse
primer (ACX: 59-GCGCCGCTTACCCTTACCCTTACCC-
TAACC-39). Each sample was mixed with 20 ul of Bromothenol
Blue loading dye and 35 ml of sample+dye and was loaded and run
at least twice using 10% non-denaturing PAGE in 1X TBE buffer.
Gels were run first at 100V for 20 min, followed by approximately
250 V for 2 h. Gels were scanned on a STORM 865 (GE
Healthcare,) and quantified using the software ImageQuant 5.2,
which integrates signal intensity over the telomere length
distribution on the gel as a function of molecular weight (GE
Healthcare).
PGE2 Measurements
Culture supernatants were harvested 72 h post-stimulation and
analyzed for PGE2 using the PGE2 EIA ELISA kit (Enzo Life
Sciences). All measurements were performed in triplicate wells and
in accordance to manufacturer’s recommendations. The sensitivity
for this kit is 13.4–2,500 pg/ml.
Measurement of Telomere Length
Genomic DNA was extracted from CD8+ T cells using the
DNeasy Tissue Kit according to manufacturer’s instructions
(Qiagen). Real-Time PCR was performed on a total of 5 ng of
DNA per sample using IQ Sybr Green Supermix according to the
manufacturer’s instructions (Bio-Rad) and an established quanti-
tative telomere PCR protocol [12]. The primers used for: Tel 1b:
39-CGGTTTGTTTGGGTTTGGGTTTGGGTTTGGGTTT-
GGGTT-59 and Tel 2b: 39-GGCTTGCCTTACCCTTACCCT-
TACCCTTACCCTTACCCT-59. HGB 1: 39-GCTTCTGACA-
CAACTGTGTTCACTAGC-59 and HGB 2: 39-CACCAACTT-
CATCCACGTTCACC-59. Genomic DNA extracted from SAOS
cells (Human osteocarcinoma cell line; American Type Culture
Collection) with known telomere length was included in each PCR
reaction to control for inter-assay variation and for comparison
among donors. A no-template control was included in all PCR
reactions, and data from all samples were expressed as a
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percentage of the telomere length of the tumor cell line, SAOS
(,23 kb), as described previously [13].
Intracellular cAMP Determination
CD8+ T cells were cultured as described, and at 72 h or 14 d
post stimulation with anti-CD2/CD3/CD28 microbeads, the cells
were pelleted and washed twice with 1xPBS. Cells were then lysed
during incubation for 20 min with HCl (0.1 M). Cell debris was
removed by centrifugation at 6006g for 10 min, and the level of
cAMP in the supernatants was determined using a direct cAMP
enzyme immunoassay kit (Enzo Life Sciences), following the
manufacturer’s protocol. Assays were performed in triplicate.
COX-2 Enzyme Activity Assay
Changes to the enzymatic activity of COX-2 were measured
using a COX enzyme activity assay (Cayman Chemical),
according to the manufacturer’s protocol. This assay measures
COX-2 activity by oxidation of the peroxidase cosubstrate TMPD
(N,N,N1,N1-tetra-methyl-p-phenylenediamine) in 96-well plates
and has been shown to accurately reflect the rate of conversion of
arachidonic acid to PGH2. In brief, CD8+ T cells were collected
72 h or 14–17 d post Ab-bead activation. Cells were then rinsed
twice in 1xPBS, lysed in ice-cold 0.1 M Tris (pH 7.8, 1 mM
EDTA), and stored at 280C until the assay was performed. The
assay mixture containing assay buffer, heme, sample (or protein
standard prepared by boiling lysates), and the COX-1 inhibitor
SC-560 to eliminate COX-1 activity (or as a control reaction the
COX-2 inhibitor DuP-697 to eliminate COX-2 activity) was
incubated for 5 min at 25uC, and TMPD was added. The
reactions were initiated by adding arachidonic acid to all wells,
and plates gently were shaken and incubated for 5 min at 25uC
and the absorbance was then read at 590 nM. COX-2 activity was
then calculated using the following formula whereby 1 unit is
defined as the amount of enzyme to oxidize 1 nmol of TMPD per
min at 25uC: COX-2 activity = [(D590/5 min/0.00826 mM-1)6
(0.21 ml/0.01 ml)]/2 (it takes two molecules of TMPD to reduce
PGG2 to PGH2) = nanomoles per minute per milliliter (units per
milliliter).
Intracellular ROS Measurement
Intracellular ROS were measured by flow cytometry using the
fluorescent probe dichlorodihydrofluorescein diacetate
(H2DCFDA, Molecular Probes), which is oxidized to highly
fluorescent dichlorodihydrofluorescein (DCF) by hydroxides,
hydrogen peroxides, and hydroxyl radicals. Briefly, T lymphocytes
(16106/ml) were treated with PGE2 and iso-PGE2 for 24 h, and
then incubated with DCFDA (2 mM) for 30 min at 37uC in the
dark. At the end of incubation, cells were washed and resuspended
in HBSS at 37uC. To determine the effects by mitochondrial
ROS, MitoSOX Red–based flow cytometric detection of mito-
chondrial superoxide was used. Cells were incubated with
MitoSOX Red superoxide indicator (Invitrogen) for 30 min and
washed, and PGE2 and iso-PGE2 were added for 2 h. The cells
were analyzed on a FACSCalibur (BD Biosciences). Analyses of
data were performed using Cell Quest Pro (BD Biosciences).
Statistical Analysis
Mean values and standard deviation as well as medians and
IQRs were calculated for each time-point. Significance was
established by the Kruskall Wallis test for between group
comparisons, a non-parametric test similar to ANOVA using
SAS V. 9.2 (SAS Institute, Cary, NC). For data where each donor
had a control sample and a treatment sample, differences were
used so that each donor could serve as his or her own control.
Differences for these data were assessed using the nonparametric
permutation test for paired data; p values of ,0.05 were
considered significant.
Results
CD8+ T Cells Upregulate Prostaglandin Receptors upon
Activation and are Sensitive to PGE2 and iso-PGE2
In order to initiate studies on the specific CD8+ T cell effects of
PGE2, it was first necessary to confirm that this subset expresses
the same PGE2-specific receptors previously reported for the total
CD3+ T cell population, namely EP2 and EP4 [7]. Figure 1A
shows that CD8+ T cells from peripheral blood of healthy donors
upregulated EP2 and EP4 mRNA and protein upon activation
with anti-CD2/CD3/CD28 microbeads, with no evidence of
expression when tested immediately ex vivo. These observations
suggest that T cell receptor (TCR) and CD28 engagement is
required for the upregulation of the EP receptors. Consistent with
previous reports, no transcripts of EP1 and EP3, the other known
EP receptors, were observed after activation (data not shown).
Therefore, these results indicate that EP2 and EP4 constitute the
major PGE2 receptors on CD8+ T cells. If similarly enhanced
receptor expression occurs in vivo, CD8+ T cells may show
increased sensitivity to the effects of PGE2 in immune-suppressed
HIV+ persons.
PGE2 has been reported to modulate function of murine T cells
and the human Jurkat T cell tumor line via cAMP-PKA signaling
[14,15]. The data in Figure 1B extend these findings to normal
human CD8+ T cells, showing that inclusion of 500 nM PGE2
and iso-PGE2 in cell culture results in a significant increase in
intracellular cAMP, which peaked shortly after exposure and
remained elevated even after 72 hours. T cells treated with
butaprost (500 nM) and misoprostal (500 nM), which are agonists
for EP2 and EP2/EP4, respectively, also showed similar levels of
intracellular cAMP (Fig. 1B). These results indicate that human
CD8+ T cells are able to recognize and be affected by PGE2 and
its free-catalyzed isoform, iso-PGE2.
Table 1. List of primers.
36B4 F-59-CAATCTGCAGACAGACACTGG-39
R-59-TCTACAACCCTGAAGTGCTTGAT-39
hTERT F-59-AAGTTCCTGCACTGGCTGATG-39
R-59-GCTTTGCAACTTGCTCCAGAC-39
CD28 F-59-AGGCTCCTGCACAGTGACTA-39
R-59-GAGCGATAGGCTGCGAAG-39
IL-2 F-59-TCACCAGGATGCTCACATTTAAGTTTT-39
R-59-TTCCTCCAGAGGTTTGAGTTCTTCTTC-39
CTLA-4 F-59TGAGTTGACCTTCCTAGATGA-39
R-59CTGGGTTCCGTTGCCTATGC-39
IFN-G F-59TCTGAGACAATGAACGCTAC-39
R-59GAGTAGGCTCACCAGGTG-39
COX-2 F-59TGCTTGTCTGGAACAACTGC-39
R-59TGAGCATCTACGGTTTGCTG-39
p16 F-59ATATGCCTTCCCCCACTACC-39
R-59CCCCTGAGCTTCCCTAGTTC-39
doi:10.1371/journal.pone.0099432.t001
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PGE2 and iso-PGE2 Decrease Proliferative Potential and
Increase the Transcription of the p16 Cell Cycle Arrest
Gene
The ability to rapidly expand in vivo upon TCR and CD28
engagement is central to T cell function and is crucial for an
effective immune response. To assess the effects of PGE2 and iso-
PGE2 on CD8+ T cell proliferative potential, we measured the
total number of population doublings (PD) of CD8+ T cell cultures
that are driven to the end stage of replicative senescence following
multiple rounds of chronic activation, as described previously
[16,17]. The end stage of replicative senescence is experimentally
defined as the inability of CD8+ T cells to enter cell cycle in
response to two rounds of stimulation, and coincides with several
functional changes, such as loss of telomerase activity and surface
expression of CD28, an important costimulatory molecule [18].
Using this cell culture protocol, we found that a 30-minute
pre-treatment with physiological concentrations of the
immunomodulators (0.05–1 mM PGE2 or iso-PGE2) prior to each
round of activation decreased the total PD in a dose-dependent
manner. PGE2 and iso-PGE2 treated T cells maximally reached a
total PD 14–16 versus 20–24 observed in diluent (DMSO)-treated
cultures (Fig. 2A). All donors followed a similar pattern of growth
when treated with PGE2 or iso-PGE2, with observed PDs 35–60%
less than control cultures. Furthermore, we tested the effects of
PGE2 and iso-PGE2 on proliferation and metabolic activity of T
cells using an MTT assay (data not shown), and found that a 4hr
incubation with the immunomodulators decreased absorbance at
570 nm by an average of 31% among three donors.
Upregulation of the cyclin dependent kinase inhibitor, p16, is a
major mediator of senescence in many cell types [17,19]. Our data
demonstrate that CD2/CD3/CD28 activation in the presence of
PGE2 and iso-PGE2 significantly increases p16 transcripts during
the later phases of the culture, i.e., 14–18 PD (p= 0.0315 for both
PGE2 and iso-PGE2) (Fig. 2B). This upregulation of the cell-cycle
Figure 1. EP receptor expression and cAMP upregulation in CD8+ T cells. CD8+ T cells were freshly isolated from PBMC from whole blood
derived from healthy donors or HIV+ persons. (A) (Left) EP2 and EP4 transcripts were evaluated by quantitative PCR in ex vivo samples and in T cells
activated with anti-CD2/CD3/CD28 microbeads for 24 hours. 36B4 was used as the housekeeping gene and data represents 3 healthy donors
performed on a single plate (*p = 0.05). (Right) EP2 and EP4 surface expression was also evaluated in healthy at 2 hours and 24 hours post activation,
or with no Ab-coated bead activation. Flow cytometric histogram shows one representative donor from a healthy person stained with PE–anti-human
EP2 or PE–anti-EP receptor antibodies (Cayman Chemical). (B) Intracellular cAMP was evaluated using a direct cAMP ELISA kit (Enzo Biosceinces) in T
cells treated with PGE2, isoPGE2, and known EP agonists, misoprostol (EP2, EP3, and EP4) and butaprost (EP2) for 72 h (n = 3; p,0.005 by Kruskal
Wallis for the comparison of all treatment groups to control).
doi:10.1371/journal.pone.0099432.g001
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arrest marker leading to premature induction of senescence-like
characteristics, if occurring in vivo, would presumably reduce the
ability of activated CD8+ T cells to expand and mount a vigorous
offense against pathogens and tumor cells.
PGE2 and iso-PGE2 Induce Premature Replicative
Senescence: Telomeres and Telomerase Activity
One of the signature features of T cell replicative senescence is
the loss in activity of telomerase, a holoenzyme that extends the
protective ends of chromosomes called telomeres [20]. The
induction of telomerase is essential for T cell proliferation and
memory T cell maintenance during infection. Loss of telomerase
in CD8+ T cells is also predictive of more rapid pathogenesis and
worse clinical outcomes in HIV disease, several cancers, age-
related bone disorders, and a host of other pathologies [21,22]. We
therefore evaluated the effects of PGE2 and iso-PGE2 on
telomerase activity and telomere length of CD8+ T cells over
time. The data in Figure 3A document that after the first two
rounds of activation, there was a dose-dependent decrease in both
transcription of hTERT, the telomerase catalytic subunit, and
actual telomerase activity in cultures exposed to PGE2 and iso-
PGE2. To elucidate the underlying mechanism for this downreg-
ulation, we treated the T cells with forskolin, a potent stimulator of
the cAMP-PKA pathway, and observed a similar pattern of
hTERT message reduction (Fig. 3A) and telomerase activity (data
not shown). In addition, H89, an inhibitor of PKA, modestly
restored some telomerase activity when pre-incubated with the
cells prior to PGE2 or iso-PGE2 addition (Fig. 3B).
As expected, the reduction of telomerase activity was associated
with telomere shortening in the PGE2- and iso-PGE2-treated cells.
The shorter telomere lengths in the treated vs. control cultures
were evident both after the same number of days in culture as well
as after identical numbers of PD, illustrated in one representative
donor (Fig. 3C). Critically short telomeres may cause the T cells to
abruptly enter permanent cell-cycle arrest, consistent with the
observed increase of p16 transcripts (Fig. 2B). Given that increased
oxidative stress is a known inducer of cellular senescence, we tested
the possibility that PGE2 and iso-PGE2 may be contributing to
accelerated telomere shortening in the T cells via induction of
reactive oxygen species (ROS). Indeed, increased mean fluores-
cence intensity of CD8+ T cells labeled with ROS-sensitive dye
DCFDA was observed in the presence of both modulators, but not
in the control cultures (Fig. 3D), reaching levels comparable to
those caused by H2O2 treatment. The MitoSOX red dye was used
to detect mitochondrial superoxide, another free radical species
thought to contribute to DNA damage and senescence. Oxidation
of MitoSOX red was observed to be modestly higher in PGE2 and
iso-PGE2 CD8+ T cells (Fig. 3D), indicating that chronic exposure
to these modulators can increase ROS production and contribute
to the development of dysfunctional phenotypes in T cells.
Key Features of T Cell Function are Modulated by PGE2
and iso-PGE2
The T cell co-stimulatory receptor, CD28, provides an
important second signal that is necessary for a robust activation
through the T cell receptor, promoting cell expansion while
preventing the induction of anergy or cell death [23]. Since loss of
CD28 gene and surface expression is a key feature of replicative
senescence, the effects of PGE2 and its free-catalyzed isoform on
CD28 were evaluated. We observed that CD28 surface expression
and CD28 transcripts were reduced in the presence of PGE2 and
iso-PGE2, with pronounced effects after the third round of
activation. In the representative experiment shown in Fig. 4A
(left panel), compared to DMSO-controls, which were nearly 49%
CD28+, the PGE2- and iso-PGE2-treated CD8+ T cells were only
,32% and ,28% CD28+, respectively. Representative time
courses for three cultures show that loss of CD28 surface
expression was more rapid in the treated cultures than in controls
(Fig. 4A). These results may explain the reduced telomerase
activity described above, since CD28 has been shown to play a
direct regulatory role on gene expression of TERT, the catalytic
subunit of telomerase, and telomerase activity [10].
Concomitant with this decline in CD28 expression was a
detectable increase in gene expression of CTLA-4, a transiently
expressed antigen that competes with CD28 for its binding
partner, B7, on antigen-presenting cells (APCs). CTLA-4 delivers
an inhibitory signal in activated T cells and thereby downregulates
T cell function and expansion [23,24]. Even after 72 hours
Figure 2. Proliferative potential decreases and p16 transcripts increase in the presence of PGE2 and iso-PGE2. T cells were activated
with anti-CD2/CD3/CD28 microbeads with or without PGE2 or iso-PGE2 and population doublings (PD) was calculated by the formula PD= log2 (final
cell concentration/initial cell concentration) (A) Long term culture of one representative donor. (B) p16 transcripts were quantified by qPCR during
early (PD4–8) and late (PD12–16) time points in the presence of PGE2, iso-PGE2 or diluent (n = 5; *p = 0.031 compared to control by the paired
permutation test). 36B4 was used as the housekeeping gene.
doi:10.1371/journal.pone.0099432.g002
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post-activation in the presence of PGE2 or iso-PGE2, CTLA-4
transcripts remained significantly higher than controls by 1.5–2
fold for PGE2 and 1.5–4 fold for iso-PGE2 (Fig. 4A - top right).
Senescence is also marked by the loss of IL-2, a cytokine that
promotes T cell survival and differentiation into effector T cells
[17]. In HIV/AIDS, IL-2 production is frequently used to assess T
cell immunity since IL-2 producing CD8+ T cells are found in
very low frequencies in viremic individuals progressing rapidly to
AIDS, compared to long-term non-progressors [13]. Furthermore,
HIV-1-specific IFN-c/IL-2-secreting CD8+ T cells support CD4-
independent proliferation of HIV-1-specific CD8+ T cells [25].
Figure 4 illustrates the significant downregulation of IL-2 mRNA
in the presence of PGE2 and iso-PGE2 during the early and late
phases of the cultures (Fig. 4B) and an observed downregulation of
the IL-2 receptor, CD25 (Fig. 4A). Studies have indicated that
dysfunctional HIV-specific T cells with features of senescence lack
responsiveness to exogenous IL-2 [26] and the downregulation of
CD25 may contribute to their inability to actively expand in vivo
[27,28].
Another important cytokine that is critical for effector function,
and whose loss is associated with senescence, is IFN-c, a potent
and multifunctional anti-viral effector molecule that is readily
secreted by CD8+ T cells upon recognition of foreign peptide
presented on HLA class I molecules. In metastatic cancers and
chronic HIV infection, loss of IFN-c-producing T cells correlates
with more rapid disease progression and worse clinical outcomes
[29,30,31]. Consistent with reports on the role of prostaglandins
on lymphocytes, PGE2 and iso-PGE2 significantly downregulated
IFN-c, measured both in the form of intracellular protein
expression (Fig. 4C) and transcript abundance (data not shown).
Also in accord with previous reports [8], TNF-a cytokine
production was decreased in the presence of the modulators
Figure 3. PGE2 and iso-PGE2 inhibit telomerase activity while increasing intracellular ROS. CD8+ T cells were negatively selected after 72
hours post activation with anti-CD2/CD3/CD28 microbeads with or without PGE2 or iso-PGE2, and inhibitors of PKA pathway. (A) (Top Left) hTERT
expression was quantified at equivalent PDs by qPCR (n = 5; *p = 0.0312; **p = 0.031 using one-sided T test because of decreased sample size for these
conditions only; n = 4). (Top Middle) Representative gel showing effects of PGE2 (10
26 to 527M) and iso-PGE2 (10
26 to 527M) on telomerase activity of
CD8+ T cells. Band intensity per lane correlates with relative telomerase activity of 1,250 CD8+ T cells in each treatment group. (B) Telomerase activity
was measured as described in (A) with PGE2 or iso-PGE2 in the presence of 1 mM of a PKA inhibitor, H89 dihydrochloride. (C) CD8+ T cell cultures were
established and chronically activated as previously described in the presence of the immune modulators. Telomere lengths were evaluated by Real-
Time PCR and expressed as a percentage of telomere length of a human tumor cell line, SAOS (,23Kb). Data represent telomere lengths over the
lifetime from 3 representative donor cultures. (D) (Top) The relative amount of intracellular ROS was determined by the mean fluorescence intensity
of DCFDA–stained, live CD8+ T cells after 24 h of culture with media alone or in the presence of PGE2, isoPGE2, ox-LDL, or H2O2 (pos control). (Bottom)
Representative flow cytometry profile of MitoSOX red oxidation in PGE2- and iso-PGE2-treated T cells.
doi:10.1371/journal.pone.0099432.g003
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(Fig. 4C). These data demonstrate significant impairments in
CD8+ T cell function caused by PGE2 and iso-PGE2, ranging
from the cells’ ability to express the costimulatory molecule CD28
to the secretion of important anti-viral cytokines. Taken together,
these data suggest that PGE2 and iso-PGE2 promote the
acquisition of multiple senescent features and may therefore play
a key role in the accumulation of dysfunctional CD8+ T cells seen
in chronic infections and cancer.
COX-2 Activity and EP4 Expression Increases in T cells
during Chronic Activation
The data presented thus far have focused on the effects of
exogenous PGE2 and iso-PGE2 on repeatedly activated CD8+ T
cells. However, we wondered whether the chronic activation in
itself might result in increased production of PGE2, mediated by
COX-2, which synthesizes PGE2 from arachidonic acid released
from the plasma membrane. This possibility would be consistent
with a report documenting observed elevated intracellular cAMP
and the fact that COX-2 inhibitor therapy reduces features of
immune dysfunction and exhaustion in CD8+ T cells in HIV-
infected persons [3]. We therefore examined COX-2 gene
expression and activity in chronically activated T cells.
Figure 5A shows that in cultures from healthy donors, there was
a dramatic increase in COX-2 transcripts 24 hours after CD2/
CD3/CD28 engagement. Furthermore, repeated rounds of
stimulation were associated with progressively increasing expres-
sion of COX-2 and EP4 transcripts, COX-2 activity and PGE2 in
culture supernatants (Fig. 5A). Elevated intracellular cAMP
(Fig. 5B – control cultures) was also detected in these ‘‘older’’ T
cell cultures, suggesting that the modulation of the cAMP-PKA
signaling pathway by TCR and CD28 engagement may signifi-
cantly change during chronic activation, as seen in cancer, HIV
infection and aging.
Figure 4. Key features of T cell function are modulated by PGE2 and isoPGE2. (A) (Top Left) CD8+ T cells treated with iso-PGE2 (top) and
PGE2 (bottom) were immunostained with FITC–anti-CD25, PE–anti-CD28, and gated on PerCP–anti-CD8 and APC–anti-CD3+ T cells (all BD
Biosciences). Samples were compared at the same PD. (Top Middle) The %CD28+cells from different treatment samples over the lifetime of the
culture in five donors; *p = 0.031 (Top right) CD28 and CTLA-4 expression was determined by qPCR during both early (PD4–8) and late (PD12–16)
culture stages in CD8+ T cells treated with the immunomodulators (n = 5; *p = 0.031). All samples were tested in triplicate and normalized to the
housekeeping gene 36B4 (B) IL-2message was similarly quantified by qPCR as in (A) after treatment (n = 5; *p = 0.031) (C) CD8+ T cells were stimulated
with Ab-coated microbeads for 72 h in the presence of PGE2, iso-PGE2, or were treated with diluent (DMSO). Intracellular IFN-c and TNF-a was
analyzed flow cytometrically using FITC–anti-TNF-a, PE–anti–IFN-c, PerCP–anti-CD8 and APC–anti-CD3. The frequencies of the IFN-c– and TNF-a
producing cells in T-cell fractions gated on CD3+CD8+ are shown as percentages.
doi:10.1371/journal.pone.0099432.g004
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COX2 Inhibition may Prevent the Development of
Features of CD8+ T Cell Dysfunction
The data shown in Fig. 5A suggest that upregulation of COX-2
activity and subsequent increase in secreted PGE2 during chronic
T cell activation may contribute to the development of features of
replicative senescence associated with persistent infections, cancer
and aging. To address one potential therapeutic approach, we
investigated whether COX-2 inhibition in mid-to-late culture (i.e.
PD12–20) would retard some of the features of replicative
senescence described above. T cells were activated as previously
described after a 30 min pretreatment with the highly specific
COX-2 inhibitor, CAY10404. The specificity and activity of the
COX-2 inhibition was first validated by measuring intracellular
cAMP in CD8+ T cells after TCR and CD28 engagement
(Fig. 5B). Pretreatment of CD8+ T cells with CAY10404 resulted
in higher mean levels of CD28 and IL-2 transcripts (2-fold and 1.8-
fold, respectively, over DMSO-control at the 6th round of
stimulation) (Fig. 5C). The data suggest that endogenous COX-2
activity and production of PGE2 may contribute to the develop-
ment of immune senescence, and that reducing COX-2 activity
may retard some of its features. Together, these results suggest
potential therapeutic benefits of COX-2 inhibition in slowing the
senescence trajectory of CD8+ T cells that arise during chronic
activation.
Discussion
The current study represents the first report documenting the
effects of PGE2 and iso-PGE2 on the senescence trajectory of
Figure 5. COX-2 activity and EP4 expression increases in T cells during chronic activation. (A) (Top left) COX-2 transcripts were quantified
by qPCR in ex vivo and activated (anti-CD2/CD3/CD28) CD8+ T cell samples from healthy donors. Each sample was tested in triplicate and normalized
to the housekeeping gene 36B4 (n = 5; *p = 0.031). Supernatants from early and late cultures from 3 donors were collected 72 h post activation with
Ab-coated microbeads and their average PGE2 concentration was calculated from triplicate wells, *p = 0.05. (Top Right) COX-2 and EP4 transcripts
were quantified 72 h post each round of activation in four healthy donors. Each sample was tested in triplicate and normalized to the housekeeping
gene, 36B4. In addition, COX-2 activity was determined in CD8+ T cells at early and late time points 72 h post activation and at quiescence (15–17 d
post stimulation) in three healthy donors using the COX Activity Assay (Cayman Chemical). (B) CD8+ T cells were pre-incubated with a highly specific
COX-2 inhibitor CAY10404 (1 mM) (Cayman Chemical) or diluent (DMSO) for 30 min and then activated with Ab-coated microbeads as described.
16106 CD8+ T cells were collected 24h post activation during early and late PDs and intracellular cAMP was measured in triplicate using a direct
cAMP ELISA kit (Enzo Life Sciences) (n = 4; *p = 0.05). (C) CD8+ T cells were cultured in the presence of 1 mM CAY10404 or DMSO for 30 min, and then
activated with Ab-coated microbeads. 72 h after each round of activation, cells were collected and IL-2 and CD28 transcripts were quantified by qPCR.
Each sample was tested in triplicate and normalized to the housekeeping gene 36B4 (n = 5; *p = 0.031).
doi:10.1371/journal.pone.0099432.g005
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human CD8+ T cells, in particular with regard to their CD28
expression, IL-2 transcription and telomerase activity. It provides
a potential mechanism by which cancer cells, aged APCs, and
HIV infection promote immune dysfunction and inefficient
surveillance during chronic activation. To our knowledge, this is
also the first documentation of the cAMP-PKA pathway in
modulating telomerase and CD28 expression. One recent study
found that this signaling cascade is a regulator of IL-2 expression
[32], but it was unclear how the critical players of the cAMP-PKA
pathway, which cross talks with such pathways as NFAT and
MAPK/ERK, affect expression of hTERT and CD28. Interest-
ingly, it has been reported that PKA increases phosphorylation of
the Wilms tumor suppressor (WT1) protein, a potent transcrip-
tional repressor that inhibits hTERT expression by direct binding
to the hTERT promoter. This observation suggests that the effects
of PGE2 can also be a result of its ablation of IL-2 signaling via
blockade of JAK3 activation [32], thereby suppressing the cell’s
ability to proliferate, which would then lead to the loss of
telomerase.
In the course of these experiments, we also observed that
pretreatment of CD8+ T cells with PGE2 and iso-PGE2 leads to a
marked reduction of surface expression of IL-7R (CD127) during
chronic activation (data not shown). The presence of CD127 on
CD8+ T cells during the antiviral immune responses is thought to
be a biomarker of effector T cells that successfully mature into
highly proliferative protective memory T cells [33,34]. Thus, loss
of CD127 expression would be detrimental to long-term memory
T cell maintenance and immune surveillance. In addition, many of
the PGE2-associated inhibitory effects on CD8+ T cells including
reductions in hTERT transcription, telomerase activity, and
proliferative potential, were even more pronounced by its free-
catalyzed isoform, iso-PGE2. This highlights a potential avenue by
which free radicals, which can directly induce the peroxidation of
arachidonic acid in the lipid membrane to produce this
isoprostane, may weaken effector T cell functions and prolifera-
tion.
An unexpected finding of our study was that chronic activation
itself amplifies COX-2 activity and production of PGE2. If this
scenario occurs in vivo, the secreted PGE2 could directly interact
with cell populations–including those of the immune system–
within the local microenvironment. Although other cell types, such
as myeloid and stromal cells, secrete the major portion of PGE2
in vivo, the production of this small-molecule derivative by T cells
can affect other cells in a paracrine manner, possibly inducing
maturation of dendritic cells and promoting active inflammation
through its role as a vasodilator [8]. Indeed, the upregulation of
COX-2 activity by T cells may enhance certain aspects of innate
immune responses while dampening others; the autologously
secreted PGE2 may also function in a negative feedback fashion to
inhibit normal CD8+ T cell effector functions [8,35]. Interestingly,
increased PGE2 was recently detected in cervical tissue samples
from women who were HIV-1 positive [36], implicating a
potential causative relationship between chronic activation and
PGE2 production by a variety of cell types. Clearly, COX-2 and
PGE2 play a complex, sometimes paradoxical role, in immunity.
Future in vivo studies will clearly be required in order to define the
role of PGE2 secretion on and by T cells, and its effects on APCs
and inflammation during chronic activation.
Finally, our study began to address possible therapeutic
strategies to diminish the deleterious in vivo effects of PGE2. Since
COX-2 activity was found to increase with each round of T cell
activation, it seemed that COX-2 inhibition might be a promising
approach to enhance T cell function, while simultaneously
inhibiting secretion of PGE2 by certain tumor cells. Although
our data (Fig. 5C) support this notion, clinical observations
regarding the negative cardiac effects of the widely prescribed
COX-2 inhibitor, celecoxib, suggest that other methods might be
preferable for enhancing immunity. For example, blockade via
knockdown or antagonists of alternative targets, including the
major receptors, EP2 and EP4, or Microsomal prostaglandin E2
synthase-1 (mPGES-1), which catalyzes the formation of PGE2
from PGH2 downstream of COX-2, may be alternative thera-
peutic strategies to prevent accelerated acquisition of senescent
features in T cells. Future in vitro and in vivo studies should clarify
the utility and safety of the EP receptor or mPGES-1 blockade as
therapeutic targets.
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